Sammyall, thanks for the reminder, but you haven't made me sleep any easier. So PAR's patents are for BME, not OA. Does that mean anyone can treat OA with PPS without infringing the patent? Can Bene sell PPS to a competitor if it's for 'pain relief'? Can a Big Pharma company run a combined safety-efficacy trial using the Indian PPS for OA and have a drug on the market 2 years after Zilosul without patent infringement?
This is the problem with relying on compounds that are off-patent.
Paradigm Ip Patents/ Trademarks, page-8
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 33599 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 65498 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |